Data sources SEC Form 4 4h ago
House PTR 4h ago
SEC 13F 4h ago
Robinhood Chain 4h ago
SOLENO THERAPEUTICS INC (SLNO) · INSIDER
Public company SOLENO THERAPEUTICS INC SLNO CIK 0001484565
Disclosed transactions 28
Buys / sells 0 / 6
Max Insider Score 33
Connections with evidence 6
Customize layout
SLNO · disclosed activity on price
Score Actor Security Side Value Executed Disclosed Lag Source Evidence 5 HF Huang Michael F. Sr. VP of Clinical Development
SLNO SOLENO THERAPEUTICS INC Disposition to issuer
D — 110.0K sh
May 18, 2026 May 18, 2026
9 JM Joshi Manher Chief Development Officer
SLNO SOLENO THERAPEUTICS INC Disposition to issuer
D — 4,700 sh
May 18, 2026 May 18, 2026traded May 18, 2026
+0d SEC Form 4 Evidence
Evidence Close
5 HF Huang Michael F. Sr. VP of Clinical Development
SLNO SOLENO THERAPEUTICS INC Disposition to issuer
D — 13.8K sh
May 18, 2026 May 18, 2026traded May 18, 2026
+0d SEC Form 4 Evidence
Evidence Close
5 HF Huang Michael F. Sr. VP of Clinical Development
SLNO SOLENO THERAPEUTICS INC Disposition to issuer
D — 39.8K sh
May 18, 2026 May 18, 2026traded May 18, 2026
+0d SEC Form 4 Evidence
Evidence Close
9 JM Joshi Manher Chief Development Officer
SLNO SOLENO THERAPEUTICS INC Disposition to issuer
D — 20.2K sh
May 18, 2026 May 18, 2026traded May 18, 2026
+0d SEC Form 4 Evidence
Evidence Close
9 JM Joshi Manher Chief Development Officer
SLNO SOLENO THERAPEUTICS INC Disposition to issuer
D — 72.3K sh
May 18, 2026 May 18, 2026traded May 18, 2026
+0d SEC Form 4 Evidence
Evidence Close
5 HF Huang Michael F. Sr. VP of Clinical Development
SLNO SOLENO THERAPEUTICS INC Disposition to issuer
D — 11.9K sh
May 18, 2026 May 18, 2026traded May 18, 2026
+0d SEC Form 4 Evidence
Evidence Close
33 HF Huang Michael F. Sr. VP of Clinical Development
SLNO SOLENO THERAPEUTICS INC Open-market sale
SELL $128K 4,256 sh
Mar 27, 2026 Mar 31, 2026traded Mar 27, 2026
+4d SEC Form 4 Evidence
Evidence Close
26 HF Huang Michael F. Sr. VP of Clinical Development
SLNO SOLENO THERAPEUTICS INC Open-market sale
SELL $15K 488 sh
Mar 27, 2026 Mar 31, 2026traded Mar 27, 2026
+4d SEC Form 4 Evidence
Evidence Close
33 MM Manning Meredith Chief Commercial Officer
SLNO SOLENO THERAPEUTICS INC Open-market sale
SELL $146K 4,864 sh
Mar 27, 2026 Mar 31, 2026traded Mar 27, 2026
+4d SEC Form 4 Evidence
Evidence Close
26 MM Manning Meredith Chief Commercial Officer
SLNO SOLENO THERAPEUTICS INC Open-market sale
SELL $18K 558 sh
Mar 27, 2026 Mar 31, 2026traded Mar 27, 2026
+4d SEC Form 4 Evidence
Evidence Close
29 MM Manning Meredith Chief Commercial Officer
SLNO SOLENO THERAPEUTICS INC Open-market sale
SELL $65K 2,100 sh
Mar 27, 2026 Mar 31, 2026traded Mar 27, 2026
+4d SEC Form 4 Evidence
Evidence Close
29 HF Huang Michael F. Sr. VP of Clinical Development
SLNO SOLENO THERAPEUTICS INC Open-market sale
SELL $57K 1,838 sh
Mar 27, 2026 Mar 31, 2026traded Mar 27, 2026
+4d SEC Form 4 Evidence
Evidence Close
9 MM Manning Meredith Chief Commercial Officer
SLNO SOLENO THERAPEUTICS INC Grant or award
A — 32.8K sh
Jan 21, 2026 Jan 23, 2026traded Jan 21, 2026
+2d SEC Form 4 Evidence
Evidence Close
9 HF Huang Michael F. Sr. VP of Clinical Development
SLNO SOLENO THERAPEUTICS INC Grant or award
A — 11.9K sh
Jan 21, 2026 Jan 23, 2026traded Jan 21, 2026
+2d SEC Form 4 Evidence
Evidence Close
21 HC Hirano Patricia C SEE REMARKS
SLNO SOLENO THERAPEUTICS INC Grant or award
A — 10.4K sh
Jan 21, 2026 Jan 23, 2026traded Jan 21, 2026
+2d SEC Form 4 Evidence
Evidence Close
17 NK Norrett Kevin Chief Business Officer
SLNO SOLENO THERAPEUTICS INC Grant or award
A — 3,500 sh
Jan 21, 2026 Jan 23, 2026traded Jan 21, 2026
+2d SEC Form 4 Evidence
Evidence Close
17 HF Huang Michael F. Sr. VP of Clinical Development
SLNO SOLENO THERAPEUTICS INC Grant or award
A — 10.4K sh
Jan 21, 2026 Jan 23, 2026traded Jan 21, 2026
+2d SEC Form 4 Evidence
Evidence Close
9 JM Joshi Manher Chief Development Officer
SLNO SOLENO THERAPEUTICS INC Grant or award
A — 4,700 sh
Jan 21, 2026 Jan 23, 2026traded Jan 21, 2026
+2d SEC Form 4 Evidence
Evidence Close
9 NK Norrett Kevin Chief Business Officer
SLNO SOLENO THERAPEUTICS INC Grant or award
A — 4,000 sh
Jan 21, 2026 Jan 23, 2026traded Jan 21, 2026
+2d SEC Form 4 Evidence
Evidence Close
9 HC Hirano Patricia C SEE REMARKS
SLNO SOLENO THERAPEUTICS INC Grant or award
A — 11.9K sh
Jan 21, 2026 Jan 23, 2026traded Jan 21, 2026
+2d SEC Form 4 Evidence
Evidence Close
17 JM Joshi Manher Chief Development Officer
SLNO SOLENO THERAPEUTICS INC Grant or award
A — 4,100 sh
Jan 21, 2026 Jan 23, 2026traded Jan 21, 2026
+2d SEC Form 4 Evidence
Evidence Close
21 MM Manning Meredith Chief Commercial Officer
SLNO SOLENO THERAPEUTICS INC Grant or award
A — 28.6K sh
Jan 21, 2026 Jan 23, 2026traded Jan 21, 2026
+2d SEC Form 4 Evidence
Evidence Close
9 HF Huang Michael F. Sr. VP of Clinical Development
SLNO SOLENO THERAPEUTICS INC Tax withholding
F $41K 812 sh
Dec 15, 2025 Dec 17, 2025traded Dec 15, 2025
+2d SEC Form 4 Evidence
Evidence Close
9 NK Norrett Kevin Chief Business Officer
SLNO SOLENO THERAPEUTICS INC Option exercise
M — 64.3K sh
Nov 17, 2025 Nov 19, 2025traded Nov 17, 2025
+2d SEC Form 4 Evidence
Evidence Close
9 NK Norrett Kevin Chief Business Officer
SLNO SOLENO THERAPEUTICS INC Grant or award
A — 14.3K sh
Nov 17, 2025 Nov 19, 2025traded Nov 17, 2025
+2d SEC Form 4 Evidence
Evidence Close
9 JM Joshi Manher Chief Development Officer
SLNO SOLENO THERAPEUTICS INC Option exercise
M — 72.3K sh
Nov 10, 2025 Nov 12, 2025traded Nov 10, 2025
+2d SEC Form 4 Evidence
Evidence Close
9 JM Joshi Manher Chief Development Officer
SLNO SOLENO THERAPEUTICS INC Grant or award
A — 16.1K sh
Nov 10, 2025 Nov 12, 2025traded Nov 10, 2025
+2d SEC Form 4 Evidence
Evidence Close
Chief Business Officer · Nov 19, 2025
Source error Price history for SLNO is unavailable.
An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.